Gout - Complete Guide to Gout!
Answers to your Gout Questions
A new gout treatment being developed by BioCryst (NASDAQ:BCRX) has achieved positive phase 2 clinical trial results supporting the advance of the drug candidate into late stage clinical studies and boosting the company’s case for finding a drug partner to take on the compound. BioCryst, a Durham, North Carolina-based biopharmaceutical company, is studying the compound called
Continued here:
Gout treatment from BCRX shines in trials; company eyes phase 3 or partner
According to a phase II clinical trial, the drug rilonacept, which inhibits the protein interleukin-1 (IL-1), substantially reduces acute gout flares that occur at the start of uric acid-reducing therapy and is noted to be generally well tolerated with no serious infections or serious adverse events occurring in relation to the treatment. The findings of the first placebo controlled study, in …
View the original here:
Gout Flares – Rilonacept Effective, According To Clinical Trial
A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1, significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy.
See the article here:
Rilonacept significantly reduces gout flares, study suggests
( Wiley-Blackwell ) A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1, significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy.
Original post:
Clinical trial demonstrates that rilonacept significantly reduces gout flares
